The Effects of Semaglutide on Body Composition and Performance in Military Personnel

NCT06468748 on ClinicalTrials.gov · last registry update 2025-12-19

Withdrawn before anyone was enrolled. The sponsor logged completion for 27 March 2025. Primary outcome, as filed: Weight Loss. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: WITHDRAWN
Phase: P4
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: United States Army Research Institute of Environmental Medicine
Sponsor type: Fed
Enrollment: 0
Started: 2024-08-01
Primary completion: 2025-03-27 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Weight Loss

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.